Is immune checkpoint modulation a potential therapeutic option in triple negative breast cancer?
Department of Chemical Engineering and Mary Babb Randolph Cancer Center, West Virginia University, Morgantown, WV, 25606, USA. david.klinke@mail.wvu.edu.|Department of Microbiology, Immunology, and Cell Biology, West Virginia University, Morgantown, WV, 25606, USA. david.klinke@mail.wvu.edu.
David J
DJ
Klinke
D056704:Adaptive Immunity / Q000235:genetics* / Q000276:immunology; D060890:B7-H1 Antigen / Q000235:genetics / Q000276:immunology; D005260:Female; D006801:Humans; D058990:Molecular Targeted Therapy; D061026:Programmed Cell Death 1 Receptor / Q000235:genetics / Q000276:immunology; D064726:Triple Negative Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology
D060890:B7-H1 Antigen; C423236:CD274 protein, human; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor